Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)

The Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed) is a grant opportunity dedicated to improving clinical trials for rare diseases. This funding initiative welcomes applications from researchers who seek financial backing for clinical projects aimed at meeting crucial needs in advancing clinical trial readiness for rare disease research.

The primary goal of this grant is to streamline the transition of potential therapeutics or diagnostics into clinical trials, thereby maximizing their chances of success. This can be achieved through the development and testing of robust biomarkers and clinical outcome assessment measures. Additionally, this grant aims to optimize the design of upcoming clinical trials by clearly defining the presentation and progression of a rare disease. This funding opportunity is intended to bolster research activities and improve the effectiveness and efficiency of rare disease-related clinical trials.